Multiple Sclerosis: Update and management FOM Nov 2015



Similar documents
Multiple Sclerosis: An imaging review and update on new treatments.

Novel therapeutic approaches in multiple sclerosis Neuroprotective and remyelinating agents, the future of clinical trials in MS?

acquired chronic immune-mediated inflammatory condition of CNS. MS in children: 10% +secondary progressive MS: rare +primary progressive MS: rare

Disclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics

Understanding How Existing and Emerging MS Therapies Work

Treatment in Relapsing MS: Choosing Among the Options. Donald Negroski, MD

Multiple Sclerosis Update. Bridget A. Bagert, MD, MPH Director, Ochsner Multiple Sclerosis Center

FastTest. You ve read the book now test yourself

Managing Relapsing Remitting MS Risks & benefits of emerging therapies. Dr Mike Boggild The Walton Centre

New Treatment Options for MS Patients: Understanding risks versus benefits

Relapsing-remitting multiple sclerosis Ambulatory with or without aid

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

What is MS? 1. disease that affects the central nervous. Is a disease that affects both white and gray matter

Disease Modifying Therapies for MS

Disease Modifying Therapies (DMTs) in Multiple Sclerosis

Supplementary appendix

How To Use A Drug In Multiple Sclerosis

A neurologist would assess your eligibility and suitability for the DMTs.

Treatment Optimization in MS: When to Start, When to Shift, when to Stop

Using the MS Clinical Course Descriptions in Clinical Practice

06/06/2012. The Impact of Multiple Sclerosis in the Pacific Northwest. James Bowen, MD. Swedish Neuroscience Institute

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

Grand Rounds: Exploring Current Therapeutic Agents in Multiple Sclerosis Management. CME University, FreeCME.com, Powerpak.com

ß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

Disease Modifying Therapies for MS

Multiple Sclerosis (MS) Aprile Royal, Novartis Pharma Canada Inc. September 21, 2011 Toronto, ON

Progress in MS: Current and Emerging Therapies

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

The Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences

SECTION 2. Section 2 Multiple Sclerosis (MS) Drug Coverage

MRI in Differential Diagnosis

New research in primary and secondary progressive multiple sclerosis. Dr Claire McCarthy MRCP PhD Neurology SpR Addenbrooke s Hospital

Best practices for using MS disease modifying therapies

News on modifying diseases therapies. Michel CLANET CHU Toulouse France ECTRIMS

New Developments in the Treatment and Management of Multiple Sclerosis

RELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010

Natalizumab (Tysabri)

Advanced Multiple Sclerosis: Progressive MS Epidemiology

How to S.E.A.R.C.H. SM for the Right MS Therapy For You!

Current and future options of MS treatment Prof. Dr. Karl Vass, AKH Wien

Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December Reference : NHSCB/D4/c/1

A Letter From the MS Coalition

Laquinimod Polman, C. et al. Neurology 2005;64:

GENENTECH S OCRELIZUMAB FIRST INVESTIGATIONAL MEDICINE TO SHOW EFFICACY IN PEOPLE WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN LARGE PHASE III STUDY

Media Release. Basel, 8 October 2015

MULTIPLE SCLEROSIS Mercedes P Jacobson, MD, Department of Neurology Temple University School of Medicine

PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to Multiple

CNS DEMYLINATING DISORDERS

Multiple Sclerosis. Current and Future Players. GDHC1009FPR/ Published March 2013

Multiple Sclerosis Drug Discoveries - What the Future Holds

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

NHS BOURNEMOUTH AND POOLE AND NHS DORSET

Rational basis for early treatment in MS. Bonaventura Casanova Estruch Unitat d Esclerosi Múltiple Hospital Universitari la Fe València

Clinical Trials of Disease Modifying Treatments

AUBAGIO (teriflunomide) oral tablet

Medication Policy Manual. Topic: Gilenya, fingolimod Date of Origin: November 22, 2010

PCORI Workshop on Treatment for Multiple Sclerosis. Breakout Group Topics and Questions Draft

Natalizumab and the Risk of PML

Treatments for MS: Immunotherapy. Gilenya (fingolimod) Glatiramer acetate (Copaxone )

Medication Policy Manual. Topic: Betaseron, Extavia, interferon beta-1b Date of Origin: June 18, 2004

Lemtrada (alemtuzumab)

Life with MS: Striving for Maximal Independence & Fulfillment

Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis

Multiple Sclerosis in Practice. An Expert Commentary With Jeffrey Cohen, MD, PhD A Clinical Context Report

Growth in revenue from MS drugs has been driven largely by price increases over the last several years.

Review Date: March Issue Status: Approved Issue No: 2 Issue Date: March 2010

Multiple Sclerosis. Matt Hulvey BL A - 615

AUBMC Multiple Sclerosis Center

Medication Policy Manual. Topic: Plegridy, peginterferon beta-1a Date of Origin: December 12, 2014

Roche s marketing applications for review of OCREVUS (ocrelizumab) in two forms of multiple sclerosis accepted by EMA and FDA

Multiple Sclerosis Therapeutics to Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

New treatments in MS What s here and what s nearly here

Original Policy Date

Update: MRI in Multiple sclerosis

Accuracy in Space and Time: Diagnosing Multiple Sclerosis Genzyme Corporation, a Sanofi company.

New and Emerging Immunotherapies for Multiple Sclerosis: Oral Agents

Chapter 10. Summary & Future perspectives

Clinically isolated syndrome (CIS)

MSTAC Initial Application

Disclosure Statement. Multiple Sclerosis: Current Trends in Treatment. Epidemiology of MS. Multiple Sclerosis. Viral Link to MS.

PROPOSED REVISIONS TO THE CRITERIA. multiple sclerosis (RRMS)] Chapter 6 6 It is recognised that use is in only exceptional circumstances in RRMS.

Multiple Sclerosis (MS) Class Update

Transcription:

Multiple Sclerosis: Update and management FOM Nov 2015

disease prevalence per 100,000 population Stroke 1000 Alzheimer's 690 Epilepsy 650 Multiple Sclerosis 150 (120-300)* Parkinson s Disease 130 (113-164) *Cost 1,000,000 per patient

McDonald 2010 criteria for diagnosis of MS Clinical Presentation 2 attacks with objective clinical evidence of 2 lesions, or objective clinical evidence of 1 lesion and reasonable historical evidence for a prior attack 2 attacks with objective clinical evidence of one lesion 1 attack with objective clinical evidence of 2 lesions 1 attack with objective clinical evidence of 1 lesion Insidious onset suggestive of primary progressive MS Additional data needed to diagnose MS None Dissemination in space on MRI criteria a Dissemination in time on MRI criteria b Dissemination in space a and time b on MRI criteria 1 year of progression, with 2 of: Evidence for dissemination in space in the brain on MRI a Evidence for dissemination in space in the spinal cord on MRI a Positive oligoclonal bands on CSF a Dissemination in space is demonstrated by lesions in 2 of the following characteristic areas: periventricular, juxtacortical, infratentorial and spinal cord b Dissemination in time is demonstrated either by simultaneous presence of gadolinium-enhancing and non-enhancing lesions, or by new T2 lesions or gadolinium-enhancing lesions on a followup scan after an interval of at least a month CH Polman, SC Reingold, B Banwell et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol, 69(2):292 302, Feb 2011

Frequency Multiple sclerosis: Age at onset Paediatric 5% Adult onset 90% Late onset 5% Age at onset of paediatric cases 30 25 20 Male Female Total 30 25 20 15 15 10 10 5 5 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Years 0 Harding et al. JNNP 2015

Presenting symptom Multiple Sclerosis: Presentation OT MT PS ON CB BB VE OM FS FM SX SP SS UE LE UK 0 5 10 15 20 25 30 35 40 45 50 % Willis et al Eur J Neurology 2014

patient No Prevalence/100,000 Epidemiology of MS: S Wales 220 200 180 160 140 120 100 Prevalence from diagnosis/100,000 Prevalence from disese onset/100,000 50 40 30 20 10 0-10 -20-30 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 New diagnosis Inward migration Outward migration Death Change of diagnosis

Changing sex ratios 40 35 30 25 20 15 Male F emale All 10 5 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Sex ratio 1.8 : 1 4.5 : 1

MS Long term disability outcomes Prognostic markers Early motor/sphincter involvement Disease course Relapse rate Social class Age Sex MRI OCBs

Employment

Precipitants for change in employment status

Infrastructure and facilities Cardiff Neuroinflammatory Unit (3800 patients, 3000 prevalent, active case load circa 2000) Outpatient specialist clinic(s) Acute/relapse clinic Inpt beds Infusion facility Specialist Physio Consultant Specialist Clinical Neuro- Occupational Nurses Staff Trainees Research Psychologist Therapist fellow 8 3 4 1 5 1 1 Specialist tertiary services Research Institute facilities (MRC Centre)

Patient contacts per month 2000-2014

Inflammation vs degeneration (therapeutic window of opportunity)

Genetic risk and a primary role for cellmediated immune mechanisms in multiple sclerosis 102 SNPs 95 Regions - 6 secondary - 1 tertiary IMSGC & WTCCC2 Nature (2011) 476; 214-9

Pathological mechanism of disease T cell mediated inflammation and demyelination B cell cortical inflammation and demyelination Axonal degeneration Gliosis Complement mediated inflammation

Personalised biology driven therapeutic approach Alemtuzumab Anti CD52 T Cell driven pathology Eculizamab Anti-C5 Rituximab anti-cd19 Ocrelizumab Anti-CD20 Complement driven pathology B cell driven pathology

Hypothetical MS Treatment Paradigms Stepwise escalation 1 1 st line 2 nd line 3 rd line 4 th line (incl. rescue) 2 Personalised treatment Disease activity BASE THERAPY Efficacy ESCALATION THERAPY High Biologics High Cytotoxic agents /experimental therapies Moderate Oral DMTs Biologics Low Platform DMTs (ABCRE) Moderate None None Low/none Oral DMTs 3 Induction and maintenance Induction Maintenance DMTs, disease-modifying treatments.

E f f I c a c y MS: Therapeutic interventions Licensed and approved for use in UK Drug Mechanism Admin Relapse rate reduction Interferon-β (1a/1b) Immune system modulation, mechanism not clear S/c IM Glatiramer acetate Cross reactivity with and suppression of immune response against myelin basic protein S/c 20% (vs placebo) 29% (vs placebo) Teriflunomide Reversible inhibition of mitochondrial enzymes Oral 31.5% (vs placebo) Fingolimod Sphingosine-1-phosphate receptor antagonist, which prevents egress of T cells from lymph nodes, sequestering autoactive T cells in lymph tissue BG-12 Natalizumab Activation of cellular defence mechanisms against oxidative stress Blocks migration of lymphocytes into the CSF by binding to cell surface receptors, thereby preventing their binding to endothelial cell receptors and crossing the blood brain barrier Alemtuzumab Monoclonal antibody targeted at CD52, resulting in prolonged T cell depletion and modulation of the lymphocyte repertoire In development Anti-LINGO-1 (RENEW) RBN Phase 2 Inhibition of LINGO-1 oligodendrocyte precursor cell differentiation Ocrelizumab Ant CD20 IV 46% (vs IFN-β) IV Oral Oral IV IV 45% (vs placebo) 47% (vs placebo) 59% (vs placebo) 74% (vs IFN-β) 34% improvement in VEP latencies (vs placebo)

Therapeutic risk MS DMTs and side effects Bone marrow transplantation Plasma exchange Tysabri Campath Rituximab IVIG Fingolimod BG12 Laquinimod Beta Interferons Glatirimer acetate Steroids Disease aggression

Clinical deterioration of NMO following Natalizumab Author Yr N= AqP4 Outcome Jacob A 2012 3 + Increased disability, Increased T2 and Gd+ Jurynczyk M 2013 1 + Increased disability, Increased T2 and Gd+ + Increased disability, Increased T2 and Gd+ + Increased disability Kitley J 2014 1 _ Increased disability, Increased T2 and Gd+ De-Hyung L 2014 1 + Increased disability, Increased T2 and Gd+

Neurology PMC4117366 Defining the Clinical Course of Multiple Sclerosis: the 2013 revisions Lublin F et al Neurology 2014 Jul 15; 83(3): 278-286 Clinically isolated syndrome (CIS) Active Inactive Indeterminate Relapsing remitting disease (RRMS) Active Inactive Indeterminate Progressive disease (PPMS, SPMS) Active and with progression Active but without progression Not active but with progression Not active and without progression (stable disease) Active: Clinical: Radiological: Progressive disease Relapses GD+ T1 or new or unequivocally enlarging T2 lesions Clinical steadily increasing documented neurological dysfunction/disability

2 months after presentation

Thresholds for change Relative vs absolute MRI (brain +/- spinal cord) T2 new or enlarging Gd+ Atrophy T1 holes Clinical Relapses Disability progression Stopping criteria

New prescriptions per year Cardiff longitudinal prescribing patterns 1996-2014

SE Wales Cohort: DMT compliance and time on treatment

MS and long term disability outcomes Figure 3. Observed EDSS within the UoWMS cohort and the predicted EDSS using both the UoWMS and the BCMS models Lawton M

A Window of therapeutic opportunity? Disability Time in years Disease course milestones Time in years

Mean EDSS Survival analyses to disability milestones in a real life cohort 8 Basel 6 4 Monoclonal Induction 2 0 Pre ARR (SD) Post ARR (SD) Monoclonal Induction 2.28 (± 1.93) 0.28 (± 0.42 ) Injectable Induction 1.08 (± 0.97 ) 0.40 (± 1.03) Escalation 1.72 (± 2.04 ) 0.64 (± 0.54 ) % Reduction 88 63 63

Second line (mab) treatment failure Alemtuzumab Anti CD52 Clinical trials new drugs (Commonly excluded) Natalizumab Anti alpha4 integrin (Ocrelizumab) Anti CD20 Repurposed drugs/techniques AZP Statins Amiloride Rituximab CycloP Mitoxantrone BMT PEx IVIg Anti C : Eculizamab Tier 1 DMTs INF, GA, DMF, Teriflunomide, Fingolimod

MS Clinical and Research Group Cardiff Research Fellows Gillian Ingram Claire Hirst Mark Cossburn Katherine Harding Mark Wardle Seb Luppe James Hjrastjl Mark Willis Emma Tallantrye Sarah Healy Clinical Nurse Specialists Gail Weaver Gaynor Williams Rhiannon Jones Emma Horton Sarah Thomas Belinda Gunning Anne Guishard Sian Locke Physiotherapy Rhian Goodfellow Annabelle Price Occupational therapy Paula Cornelius Clinical Neuropsychology Phil Moore Paul Bradley Consultant staff Neil Robertson Trevor Pickersgill Fady Joseph Owen Pearson Valentina Tomassini Biostatistics/Epidemiology Yoav Ben-Shlomo Biochemistry and Laboratory support WMSBB Sam Loveless Sara Butterworth Bethan Dancy L Hakobyan Paul Morgan Administrative support Lucy Coates Sue Butler Alisa Jones Karen Blatchford